Associated Papers
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
Rakaee M et al.
Jama Oncology, 2026
Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
Fujino K et al.
Lung Cancer (amsterdam, Netherlands), 2025
Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
Nomura K et al.
International Journal of Cancer, 2025
Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients.
Kang YK et al.
Journal of Pathology and Translational Medicine, 2025
A patient with a Germline (p.R776H) EGFR Mutation With Multiple Lung Cancers Harboring Different Somatic EGFR Mutations.
Petrini I et al.
Clinical Lung Cancer, 2024
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening.
Suda K et al.
Cancers, 2023
Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.
Liu L et al.
Current Oncology (toronto, Ont.), 2021
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Yang X et al.
Bmc Cancer, 2021
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y et al.
Pharmacology, 2021
Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients.
Oh AC et al.
Biopreservation and Biobanking, 2019
Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA.
Hanibuchi M et al.
Oncotarget, 2019
[Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer].
Wang M et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2018
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
Zhang Y et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2017
An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
Wei WE et al.
Plos One, 2016
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
Tanaka K et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015
[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer].
Yang X et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2015
Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients.
Bichev SN et al.
Cellular Oncology (dordrecht, Netherlands), 2015
PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.
Yu J et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2013
Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung.
Fukui T et al.
Cancer Science, 2007
Methodological and TNM Focus-Based Comparison of EGFR Mutation Status in Non-Small-Cell Lung Carcinomas.
Akca Y et al.
Journal of Cytology, 0